US Bancorp
ACET icon

US Bancorp’s Adicet Bio ACET Stock Holding History

US Bancorp’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-101
Closed -$9.32K – 3983
2023
Q1 		$9.32K Buy
101
+25
+33% +$3.14K ﹤0.01% 3309
2022
Q4 		$10.9K Buy
76
+66
+660% +$16.5K ﹤0.01% 3267
2022
Q3 		$2K Buy
+10
New +$2.54K ﹤0.01% 3790
2022
Q2 		– Sell
-5
Closed -$2K – 4057
2022
Q1 		$2K Buy
+5
New +$1.15K ﹤0.01% 3794

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

US Bancorp's ACET Position: Q2 2023 in Review

US Bancorp sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 101 shares — an estimated $9.32K sold.

US Bancorp first reported a position in ACET in Q1 2022 and held it in 4 quarters. The position peaked at $10.9K in Q4 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • US Bancorp reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
  • US Bancorp sold 101 Adicet Bio shares in Q2 2023, an estimated $9.32K.
  • US Bancorp first reported a position in Adicet Bio in Q1 2022 and held it in 4 quarters.
  • US Bancorp's Adicet Bio position peaked at $10.9K in Q4 2022.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.